Xenex designs and manufactures the LightStrike Germ‑Zapping Robots, a pulsed xenon Full Spectrum UV room disinfection system that destroys viruses, bacteria and spores including C.diff, MRSA and CRE. The robots run four‑ to five‑minute cycles and, according to Xenex customers, can disinfect roughly 30–62 hospital rooms per day. Outcome studies published in peer‑reviewed journals and hospital reports cited by the company show 50–100% decreases in C.diff, MRSA and surgical site infection rates when its devices are used. Approximately 400 hospitals, Veterans Affairs and Department of Defense facilities across the U.S., Canada, Europe, Africa and Japan use Xenex robots, and the devices are also deployed in skilled nursing facilities, ambulatory surgery centers and long‑term acute care facilities. The company notes its devices contain no toxic mercury and are differentiated by the use of xenon as the UV source. Xenex plans to use new capital to grow its sales force, advance product development, expand scientific research and pursue international expansion. Xenex produces a patented pulsed‑xenon Full Spectrum UV room disinfection system (the Xenex Germ‑Zapping Robot) designed for quick, chemical‑free disinfection of patient rooms and other hospital areas. The robot runs five‑minute cycles and, according to customers, can disinfect 30–62 hospital rooms per day. More than 250 hospitals, Veterans Affairs and DoD facilities, and other care sites are using Xenex robots, and six peer‑reviewed studies have confirmed the technology's efficacy, including three showing reductions in C.diff, MRSA and other MDRO infections. Concern over outbreaks (including Ebola) and CMS penalties for hospital‑acquired infections have heightened demand for the product. The company announced it secured $25 million in new funding and plans to use the capital for product development, international expansion and increasing its U.S. sales force. Xenex positions its technology as a faster, mercury‑free alternative to other disinfection methods and aims to expand adoption in healthcare settings worldwide. Xenex Disinfection Services develops a portable pulsed xenon ultraviolet (UV) room disinfection system for healthcare facilities. Its device uses pulsed xenon UV light to destroy viruses, bacteria, mold, fungus and bacterial spores, with a five-minute disinfection cycle and portability that lets environmental services staff operate without disrupting hospital operations or using chemicals. The system contains no mercury or hydrogen peroxide and is described as a green automated room disinfection technology. Nearly 200 hospitals and Veterans Affairs facilities in the U.S. use the Xenex system, and peer-reviewed studies—including work at MD Anderson—have shown reductions in C. diff, VRE and MRSA infections (for example, a 53% C. diff reduction at Cooley Dickinson and a 56% MRSA reduction at Cone Health). Xenex recently unveiled a next-generation product design with user enhancements and says its technology is about 20 times more effective than standard chemical cleaning. The company plans to use new funding for product development, international expansion, and increasing its U.S. sales force.

Total raised

$74M

Funding rounds

3

Latest round

Equity

Latest activity

Feb 2017